PLEASANTON, Calif.--(BUSINESS WIRE)--Over the past year, growing numbers of customers are adopting Veeva Vault CTMS to empower clinical teams with one complete source of trial information for faster study execution. Vault CTMS is a next-generation cloud application from Veeva Systems (NYSE:VEEV) that unifies end-to-end information and processes for greater visibility throughout the trial lifecycle. In 15 months since the product’s availability, 28 sponsors and CROs have selected Vault CTMS and 18 customers are already using the product to streamline clinical operations and improve trial performance.
“CTMS solutions have held the industry back for decades, and the industry is recognizing the tremendous opportunity to improve efficiency throughout its operations,” said Henry Galio, senior director, Vault CTMS. “Veeva Vault CTMS is finally giving customers a new, innovative approach to CTMS for more efficient and effective trials.”
A recent survey shows that challenges with current CTMS applications are limiting trial operations for the majority of life sciences companies.1 Greater visibility is a top driver for clinical operations professionals to improve the use of CTMS. 2
“Veeva Vault CTMS gives us a full view into trial tasks and processes to make faster, more informed decisions throughout the course of a study,” said Hunter Walker, CTO, Atlantic Research Group (ARG), a CRO that specializes in managing rare disease clinical trials for multiple sponsors. “Study managers and clinical research associates have an intuitive, easy-to-use application to manage trial data, documents, and processes.”
Consistent with the industry’s focus to improve operational performance, more customers are using Vault CTMS to unify their clinical information and processes and gain a global view into study execution. Clinical teams can also leverage the same content and data across clinical operations to streamline trial processes.
“With significant clinical trial timeline pressures, we needed a CTMS solution we could implement quickly to simplify trial management across our studies,” said Jeff Reyes, R&D IT at Immunomedics. “Veeva Vault CTMS gives us a modern application that works seamlessly with other Veeva clinical applications to drive greater efficiency throughout our clinical operations.”
Vault CTMS is part of Veeva Vault Clinical Suite, the industry’s first suite of applications with CTMS, EDC, eTMF, and study start-up on a single cloud platform. Vault Clinical Suite helps companies eliminate system silos and unify clinical data management and clinical operations. Vault Clinical Suite is part of Veeva Development Cloud, a unified suite of applications for clinical, regulatory, and quality to help organizations drive end-to-end business processes across R&D and manufacturing.
Veeva also announced today the availability of Veeva Vault Submissions Publishing, a new cloud application in the Veeva Vault RIM Suite to unify publishing and submission document authoring. Read the Vault Submissions Publishing news to learn more.
Also, join 1,300 life sciences professionals and experts at the upcoming Veeva R&D Summit in Philadelphia, September 16-18. Learn more, register, and view the full agenda at veeva.com/R&DSummit.
Additional Information
For more on Veeva Vault CTMS, visit: veeva.com/VaultCTMS
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow @veevasystems on Twitter: twitter.com/veevasystems
Like Veeva on Facebook: facebook.com/veevasystems
About Veeva Systems
Veeva Systems Inc. is a leader in cloud-based software for the global life sciences industry and other regulated manufacturers. Committed to innovation, product excellence, and customer success, Veeva has more than 650 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. Veeva is headquartered in the San Francisco Bay Area, with offices throughout North America, Europe, Asia, and Latin America. For more information, visit veeva.com.
Forward-looking Statements
This release contains forward-looking statements, including the market demand for and acceptance of Veeva’s products and services, the results from use of Veeva’s products and services, and general business conditions, particularly in the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva’s financial results are included under the captions, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the company’s filing on Form 10-Q for the period ended April 30, 2018. This is available on the company’s website at veeva.com under the Investors section and on the SEC’s website at sec.gov. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.